S. Cedrés

4.3k total citations · 1 hit paper
80 papers, 2.2k citations indexed

About

S. Cedrés is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, S. Cedrés has authored 80 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Pulmonary and Respiratory Medicine, 42 papers in Oncology and 12 papers in Cancer Research. Recurrent topics in S. Cedrés's work include Lung Cancer Treatments and Mutations (31 papers), Occupational and environmental lung diseases (30 papers) and Pleural and Pulmonary Diseases (18 papers). S. Cedrés is often cited by papers focused on Lung Cancer Treatments and Mutations (31 papers), Occupational and environmental lung diseases (30 papers) and Pleural and Pulmonary Diseases (18 papers). S. Cedrés collaborates with scholars based in Spain, Palestinian Territory and France. S. Cedrés's co-authors include Enriqueta Felip, Pablo Martínez, Alejandro Navarro, Alex Martínez‐Martí, Davis Y. Torrejon, Joachim G.J.V. Aerts, Núria Pardo, Esther Zamora, Aleix Prat and Anna K. Nowak and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

S. Cedrés

73 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

2017 304 citations Joachim G.J.V. Aerts, S. Cedrés et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Cedrés Spain	20	1.3k	1.2k	363	305	272	80	2.2k
Alessandra Curioni‐Fontecedro Switzerland	24	909 0.7×	722 0.6×	398 1.1×	424 1.4×	173 0.6×	87	1.8k
Jinming Yu China	19	1.2k 0.9×	671 0.6×	579 1.6×	501 1.6×	456 1.7×	66	2.3k
Pol Specenier Belgium	21	1.1k 0.8×	542 0.5×	624 1.7×	206 0.7×	261 1.0×	84	1.9k
Alexandre Ingels France	16	594 0.4×	618 0.5×	483 1.3×	333 1.1×	249 0.9×	78	1.4k
Alessandra di Pietro Italy	21	1.1k 0.8×	687 0.6×	667 1.8×	221 0.7×	289 1.1×	95	1.9k
Virginia Ferraresi Italy	25	1.3k 1.0×	1.0k 0.9×	635 1.7×	370 1.2×	247 0.9×	125	2.4k
Sylvestre Le Moulec France	21	1.3k 0.9×	919 0.8×	706 1.9×	368 1.2×	583 2.1×	97	2.3k
Neeta Somaiah United States	30	1.4k 1.1×	1.7k 1.5×	793 2.2×	383 1.3×	341 1.3×	169	2.9k
Alfonso Gúrpide Spain	23	1.5k 1.1×	1.0k 0.9×	511 1.4×	782 2.6×	392 1.4×	75	2.5k
Feifei Teng China	21	1.6k 1.2×	674 0.6×	375 1.0×	669 2.2×	238 0.9×	54	2.3k

Countries citing papers authored by S. Cedrés

Since Specialization

Citations

This map shows the geographic impact of S. Cedrés's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Cedrés with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Cedrés more than expected).

Fields of papers citing papers by S. Cedrés

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Cedrés. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Cedrés. The network helps show where S. Cedrés may publish in the future.

Co-authorship network of co-authors of S. Cedrés

This figure shows the co-authorship network connecting the top 25 collaborators of S. Cedrés. A scholar is included among the top collaborators of S. Cedrés based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Cedrés. S. Cedrés is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nadal, Ernest, Paloma Martín-Martorell, José Carlos Benítez, et al.. (2025). Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma. Lung Cancer. 203. 108545–108545.

Cedrés, S., et al.. (2024). Treatment patterns and humanistic burden of malignant pleural mesothelioma in Spain. Clinical & Translational Oncology. 27(1). 213–222.

Hernes, Eivor, Roslyn J. Francis, Anna K. Nowak, et al.. (2024). Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine. European Journal of Nuclear Medicine and Molecular Imaging. 52(2). 693–707. 2 indexed citations

Cedrés, S., Patricia Iranzo, Ana Callejo, et al.. (2023). Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy. Cancers. 15(24). 5787–5787. 4 indexed citations

Carbonell, Caterina, Joan Frigola, Núria Pardo, et al.. (2023). Dynamic changes in circulating tumor DNA assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC. Molecular Oncology. 17(5). 779–791. 4 indexed citations

Ponce, Santiago, S. Cedrés, Charles Ricordel, et al.. (2023). ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment. Journal for ImmunoTherapy of Cancer. 11(9). e007552–e007552. 16 indexed citations

Cedrés, S., Patricia Iranzo, Ana Callejo, et al.. (2021). Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort. Scientific Reports. 11(1). 21357–21357. 10 indexed citations

Cedrés, S., Santiago Ponce-Aix, Patricia Iranzo, et al.. (2020). Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients. Clinical & Translational Oncology. 22(8). 1390–1398. 8 indexed citations

Gonzalez, N. Saoudi, Patricia Iranzo, Ana Callejo, et al.. (2020). 1798P Carboplatin-paclitaxel (CP) chemotheraphy as salvage treatment for small cell lung cancer (SCLC): A real-world evidence analysis. Annals of Oncology. 31. S1041–S1041. 1 indexed citations

10.

Matos, Ignacio, María Vieito, Irene Braña, et al.. (2020). 572P Limited efficacy of immunotherapy combination regimens in patients with unselected “cold” tumours enrolled in early clinical trials. Annals of Oncology. 31. S489–S489. 1 indexed citations

11.

Ceresoli, Giovanni Luca, Joachim G.J.V. Aerts, Rafał Dziadziuszko, et al.. (2019). Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. The Lancet Oncology. 20(12). 1702–1709. 107 indexed citations

12.

Aguado, Carlos, Manuel Dómine, Antonio Calles, et al.. (2018). 159P Clinical activity of afatinib in a cohort of patients with lung adenocarcinoma harbouring uncommon EGFR mutations: A Spanish retrospective multicentre study. Journal of Thoracic Oncology. 13(4). S95–S96. 1 indexed citations

13.

Prat, Aleix, Alejandro Navarro, Laia Paré, et al.. (2017). Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Cancer Research. 77(13). 3540–3550. 277 indexed citations

14.

Remón, Jordi, Alex Martínez‐Martí, Enric Carcereny, et al.. (2017). Major pathological response after preoperative chemotherapy as a surrogate marker of survival in early-stage non-small cell lung cancer: cohort of NATCH phase III trial. Annals of Oncology. 28. v454–v454. 7 indexed citations

15.

Grosso, Federica, Rodryg Ramlau, S. Cedrés, et al.. (2017). OA22.01 STELLAR - Interim Results of a Phase 2 Trial of TTFields with Chemotherapy for First Line Treatment of Malignant Mesothelioma. Journal of Thoracic Oncology. 12(1). S329–S329. 2 indexed citations

16.

Martínez‐Martí, Alex, Enriqueta Felip, Judit Matito, et al.. (2017). DualMET andERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). Annals of Oncology. 28(10). 2451–2457. 55 indexed citations

17.

Martínez, Pablo, Javier Hernández‐Losa, S. Cedrés, et al.. (2013). Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients. PLoS ONE. 8(1). e52261–e52261. 55 indexed citations

18.

Cedrés, S., Esther Zamora, Pablo Martínez, et al.. (2013). Expression of Wilms’ tumor gene (WT1) is associated with survival in malignant pleural mesothelioma. Clinical & Translational Oncology. 16(9). 776–782. 15 indexed citations

19.

Felip, Enriqueta, et al.. (2010). How to integrate current knowledge in selecting patients for first line in NSCLC?. Annals of Oncology. 21. vii230–vii233. 5 indexed citations

20.

Reck, Martin, Norbert Frickhofen, S. Cedrés, et al.. (2010). Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study. Lung Cancer. 70(2). 180–187. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact